Program
pralatrexate
Also written as “Pralatrexate Injection”, “Pralatrexate” and “Folotyn”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Cutaneous · Hematologic Neoplasms · Lymphoma, B-Cell, led by 3 companies.
Drug pagePralatrexate: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aurobindo Pharmaits history only | 122 open or running | phase 3since Sep 19, 2023 | Aug 14, 2006 | Feb 2027phase 1 · NCT07036133 |
| Zydus Lifesciencesits history only | 40 open or running | phase 3since Aug 18, 2011 | Jan 24, 2003 | none ahead |
| Mundipharma | 30 open or running | phase 4since May 5, 2017 | Dec 4, 2013 | none ahead |
Also a collaborator on its studies: Axis Clinicals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mundipharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 4, 2013First study: phase 2 study in Lymphoma, T-Cell, PeripheralFirst studyNCT02013362 · 25 enrolled · Japan
- Jul 26, 2016Phase 3 study in Lymphoma, T-Cell, PeripheralNCT03349333 · 85 enrolled · China
- May 5, 2017Phase 4 study in Lymphoma, T-Cell, PeripheralNCT03150602 · 22 enrolled · Taiwan
TargetBeta
“A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities”NCIt, by rule
“Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Studies
All 3 Mundipharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03150602Lymphoma, T-Cell, Peripheral · Taiwan | 4 | UNKNOWN | Dec 31, 2020 | 22 |
| NCT03349333Lymphoma, T-Cell, Peripheral · China | 3 | Completed | Jul 21, 2017 | 85 |
| NCT02013362Lymphoma, T-Cell, Peripheral · Japan | 2 | Completed | Dec 2015 | 25 |
How it is read
Names in the registry
- “Pralatrexate Injection”, 9 entries
- “Pralatrexate”, 4 entries
- “pralatrexate”, 2 entries
- “Folotyn”, 2 entries
- “Folotyn and Leucovorin”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 8 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Lymphoma, T-Cell, Cutaneous, 2 studies
- Hematologic Neoplasms, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.